Ocugen is helping Bharat Biotech develop the vaccine candidate for the U.S. market. Covaxin is a highly purified and inactivated vaccine manufactured using a Vero cell manufacturing platform. Covaxin has demonstrated 78% efficacy against COVID-19, according to recently published interim phase III clinical results.
In a number of studies, researchers from the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV) found that Covaxin is effective not only against the Brazil variant but also against the U.K. and Indian variants, according to Ocugen. The vaccine is being developed in a collaboration between Bharat Biotech and ICMR-NIV.
Copyright © 2021 scienceboard.net